The MyeCare Program has been designed to comply with the Australian Privacy Principles (APPs) and is committed to managing personal information in an open, transparent and secure way.
GlaxoSmithKline Australia Pty Ltd (GSK) has engaged Partizan Worldwide Pty Ltd now part of the DKSH Group (Partizan Worldwide) to administer the MyeCare Program. In order to provide MyeCare Program services to you, Partizan Worldwide will collect and hold some of your personal information. This notice should be read in conjunction with DKSH's Privacy Notice.
To participate in the MyeCare Program, you need to enrol and consent to the MyeCare Program Terms and Conditions. For the MyeCare Program to provide you with program services, some personal information will need to be collected. For participants this includes your name, age, street address, email address and telephone number and relevant treatment information. For HCPs this includes your name, email address, phone number plus clinic/hospital name, state and postcode. Importantly, personal information of enrolled participants will not be shared with GSK.
If you choose not to provide the information requested, it may not be possible for the MyeCare team to contact you or provide program services as part of the MyeCare Program.
Sensitive personal information will be used by the MyeCare Program team to contact patients and Healthcare Professionals, create an enrolment record; and enter into the MyeCare Program registries, databases and web-based systems hosted in Australia.
Sensitive personal information provided may be disclosed by Partizan Worldwide to the patient’s nominated Healthcare Practitioner(s) or to third party individuals or organisations contracted or involved in the administration of the MyeCare Program located within Australia such as:
Should you experience an adverse event or product complaint, Partizan Worldwide will need to provide this to GSK, who may be required to report this to relevant regulatory authorities, even if it has already been reported by you directly to a doctor or the local regulatory authority.
GSK monitors the use of its medicines and actively assesses the balance between their benefits and risks.
GSK, or a third party acting on their behalf, may contact a patient’s Healthcare Professional in order to collect further information related to an adverse event. Your de-identified personal information may be processed by GSK, its affiliated companies and GSK’s trusted third party suppliers outside Australia. GSK implement appropriate measures to ensure that your de-identified personal information remains protected and secure when it is transferred outside Australia, in accordance with applicable data protection and privacy laws.
When an adverse event is reported, GSK may disclose de-identified personal or sensitive information to regulatory authorities, such as the FDA (Food and Drug Administration) or EMA (European Medicines Agency). This disclosure is strictly limited to the purpose of fulfilling regulatory requirements for adverse event reporting.
De-identified information relating to a patient’s participation in the MyeCare Program may also be collated into a report for GSK. GSK may use this information to:
GSK may also share de-identified information with its parent Company or its affiliates regarding how the Program is working on an aggregated basis. This information does not identify patients individually. Any personal information collected by GSK will be handled in accordance with GSK’s privacy notice available at General Privacy Notice.
Partizan Worldwide (or third party individuals or organisations contracted or involved in the administration of the MyeCare Program) will retain the sensitive personal information collected for the period of your participation in the MyeCare Program and after your participation in the Program has ended for the purposes of reporting, audit and as required by law. Retention of sensitive personal information is also regulated by medical legislation. Any sensitive personal information relating to adverse event reporting must be retained for ten years after the active ingredient within a particular product (or product line) is no longer licensed, in development or production by GSK or by a contracted third party.
At your request, Partizan Worldwide (or third party individuals or organisations contracted or involved in the administration of the MyeCare Program) will update your personal information as it changes during the course of your participation in the MyeCare Program.
Please contact the Privacy officer at Partizan Worldwide, Level 8/321 Kent Street, Sydney NSW 2000 or info@partizanhealth.com:
From time to time, we will update this Privacy Notice. Any changes become effective when we share the revised Privacy Notice with you.
If you have any questions about your condition or treatment, please contact your treating healthcare professional.
If you have any questions about MyeCare, please call the Program team on 1800 140 272, Monday to Friday 9am - 5pm (AEST).
For more information about your treatment and medical advice, please consult your healthcare professional.
The MyeCare Program has been developed and supported by GlaxoSmithKline Australia Pty Ltd, and is managed by Partizan Worldwide Pty Ltd (an independent provider of patient support services). Partizan Worldwide Pty Ltd, Level 8/321 Kent Street, Sydney NSW 2000. ABN: 18 115 985 825. GlaxoSmithKline Australia Pty Ltd. ABN 47 100 162 481. Melbourne, VIC. Trademarks are owned by or licensed to the GSK group of companies. © 2025 GSK group of companies or its licensor. NX-AU-MMU-PSP-250004 Date of approval: September 2025